DE60142237D1 - Cd30 oder cd30l antagonisten zur behandlung von autoimmun und kronisch entzündlichen zuständen - Google Patents

Cd30 oder cd30l antagonisten zur behandlung von autoimmun und kronisch entzündlichen zuständen

Info

Publication number
DE60142237D1
DE60142237D1 DE60142237T DE60142237T DE60142237D1 DE 60142237 D1 DE60142237 D1 DE 60142237D1 DE 60142237 T DE60142237 T DE 60142237T DE 60142237 T DE60142237 T DE 60142237T DE 60142237 D1 DE60142237 D1 DE 60142237D1
Authority
DE
Germany
Prior art keywords
treatment
agents
cronically
autoimmun
flammable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60142237T
Other languages
English (en)
Inventor
Kendall M Mohler
Dauphine S Barone
Jacques J Peschon
Mary K Kennedy
John D Pluenneke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DE60142237D1 publication Critical patent/DE60142237D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60142237T 2000-08-08 2001-08-06 Cd30 oder cd30l antagonisten zur behandlung von autoimmun und kronisch entzündlichen zuständen Expired - Lifetime DE60142237D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22407900P 2000-08-08 2000-08-08
PCT/US2001/024783 WO2002011767A2 (en) 2000-08-08 2001-08-06 Methods for treating autoimmune and chronic inflammatory conditions using antagonists of cd30 or cd30l

Publications (1)

Publication Number Publication Date
DE60142237D1 true DE60142237D1 (de) 2010-07-08

Family

ID=22839207

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60142237T Expired - Lifetime DE60142237D1 (de) 2000-08-08 2001-08-06 Cd30 oder cd30l antagonisten zur behandlung von autoimmun und kronisch entzündlichen zuständen

Country Status (10)

Country Link
US (5) US6652854B2 (de)
EP (1) EP1307225B1 (de)
JP (1) JP4938957B2 (de)
AT (1) ATE468860T1 (de)
AU (2) AU2001281163B2 (de)
CA (1) CA2417984C (de)
DE (1) DE60142237D1 (de)
ES (1) ES2346184T3 (de)
MX (1) MXPA03000983A (de)
WO (1) WO2002011767A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220103A1 (en) * 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
US20040018194A1 (en) * 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
WO2003009863A1 (en) * 2001-07-26 2003-02-06 Genset S.A. Agonists and antagonists of cofoxin for use in the treatment of metabolic disorders
US20040096446A1 (en) * 2001-08-17 2004-05-20 Lane Thomas E. Methods for treating demyelinating diseases
US20040170602A1 (en) * 2002-01-04 2004-09-02 Desjarlais John R. Dominant negative proteins and methods thereof
EP1576088A4 (de) * 2002-01-04 2006-09-06 Xencor Inc Dominant-negative proteine und verfahren dazu
KR100668538B1 (ko) * 2002-01-09 2007-01-16 메다렉스, 인코포레이티드 Cd30에 대한 인간 모노클로날 항체
GB0202769D0 (en) * 2002-02-06 2002-03-27 Univ Cambridge Tech Polypeptides methods and means
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
EP1378523A1 (de) * 2002-07-01 2004-01-07 STEIN, Harald, Prof. Dr. Anti-cd30-antikörper und deren verwendungen
US7208579B2 (en) * 2003-05-30 2007-04-24 The Regents Of The University Of California IL4 receptor antagonists for horse, dog and cat
WO2005037314A1 (en) * 2003-08-20 2005-04-28 Centocor, Inc. Method for generating antibodies
DK1667730T3 (da) * 2003-08-20 2013-09-23 Univ Miami Sammensætninger og fremgangsmåder til behandling af inflammatorisk lungesygdom
WO2005023201A2 (en) * 2003-09-09 2005-03-17 Medarex, Inc. Methods for treating rheumatoid arthritis
DE602004021949D1 (de) * 2003-09-10 2009-08-20 Hoffmann La Roche Anti-interleukin-1 rezeptor antikörper und deren verwendung
AR045614A1 (es) * 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
MXPA06005941A (es) * 2003-12-10 2006-08-23 Medarex Inc Anticuerpos ip-10 y sus usos.
US7955703B2 (en) * 2004-07-12 2011-06-07 Lintec Corporation Silicone rubber based pressure sensitive adhesive sheet
US20060069436A1 (en) * 2004-09-30 2006-03-30 Depuy Spine, Inc. Trial disk implant
CN101056655A (zh) * 2004-10-01 2007-10-17 米德列斯公司 治疗cd30阳性淋巴瘤的方法
US11268149B2 (en) 2004-12-08 2022-03-08 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease
TWI444187B (zh) * 2005-01-25 2014-07-11 Synta Pharmaceuticals Corp 用於炎症及免疫相關用途之噻吩化合物
BRPI0607203A2 (pt) 2005-02-18 2009-08-25 Medarex Inc anticorpo anti-cd30 isolado, célula hospedeira, métodos para inibir o crescimento de células cd30+, e, uso de um anticorpo anti-cd30 desfucosilado
WO2006116246A2 (en) * 2005-04-25 2006-11-02 Medarex, Inc. Method of treating cd30 positive lymphomas
US20070009479A1 (en) * 2005-06-17 2007-01-11 Aerovance, Inc. Methods for treating dermatitis using mutant human IL-4 compositions
CA2621083C (en) 2005-08-30 2017-04-11 University Of Miami Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins
SG166788A1 (en) * 2005-10-28 2010-12-29 Centocor Inc Use of b cell expansion agents in generating antibodies
WO2007084672A2 (en) * 2006-01-17 2007-07-26 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
CA2635445A1 (en) * 2006-02-22 2007-08-30 University Of Zurich Methods for treating autoimmune or demyelinating diseases
JPWO2007097056A1 (ja) * 2006-02-23 2009-07-09 イビデン株式会社 ハニカム構造体および排ガス浄化装置
EP2010214A4 (de) 2006-04-10 2010-06-16 Abbott Biotech Ltd Verwendung und zusammensetzungen zur behandlung von rheumatoider arthritis
US20100178652A1 (en) * 2007-01-05 2010-07-15 Litherland Sally A Materials and Methods for the Detection, Prevention and Treatment of Autoimmune Disease
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
CN102770455B (zh) 2009-08-03 2017-02-08 迈阿密大学 用于体内扩增调节性t细胞的方法
EP2675467A4 (de) * 2011-02-18 2014-06-25 Merck Sharp & Dohme Verwendung von mdl-1-antagonisten zur behandlung von spondylarthropathie
CN103619880A (zh) 2011-04-29 2014-03-05 百时美施贵宝公司 Ip-10抗体剂量递增方法
EP3929208A1 (de) * 2012-04-27 2021-12-29 Amgen Inc. Menschliches cd30-ligandantigen bindende proteine
JP2016504045A (ja) 2013-01-09 2016-02-12 ザ ユニバーシティー オブ マイアミThe University Of Miami TL1A−Ig融合タンパク質を用いる制御性T細胞の制御のための組成物及び方法
US10556948B2 (en) 2015-11-30 2020-02-11 Bristol-Myers Squibb Company IP-10 antibodies and their uses
AU2019261933A1 (en) * 2018-04-30 2020-12-03 Cedars-Sinai Medical Center Methods and systems for selection and treatment of patients with inflammatory diseases
WO2020096046A1 (ja) * 2018-11-09 2020-05-14 国立大学法人大阪大学 老化関連t細胞を標的とした糖代謝異常の予防または治療用ワクチン
MX2023009621A (es) * 2021-02-17 2023-10-31 Prometheus Biosciences Inc Anticuerpos anti-cd30l y usos de estos.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5304635A (en) 1990-03-12 1994-04-19 University Of Southern California Antigen specifically expressed on the surface of B cells and Hodgkin's cells
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
WO1993024135A1 (en) 1992-05-26 1993-12-09 Immunex Corporation Novel cytokine that binds cd30
EP0672141B1 (de) 1992-10-23 2003-05-14 Immunex Corporation Methoden zur herstellung löslicher, oligomerer proteine
US5670527A (en) * 1993-07-16 1997-09-23 Smithkline Beecham Corporation Pyridyl imidazole compounds and compositions
EP1053316A1 (de) * 1998-02-06 2000-11-22 AbGen GmbH Nukleinsäuren zur modulation zellulärer aktivierung
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
WO2003043583A2 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies

Also Published As

Publication number Publication date
US6652854B2 (en) 2003-11-25
MXPA03000983A (es) 2003-10-06
US20080213259A1 (en) 2008-09-04
EP1307225B1 (de) 2010-05-26
WO2002011767A2 (en) 2002-02-14
US7273609B2 (en) 2007-09-25
JP4938957B2 (ja) 2012-05-23
AU2001281163B2 (en) 2006-03-30
JP2005503319A (ja) 2005-02-03
ATE468860T1 (de) 2010-06-15
CA2417984C (en) 2011-08-02
US7122183B2 (en) 2006-10-17
CA2417984A1 (en) 2002-02-14
AU8116301A (en) 2002-02-18
ES2346184T3 (es) 2010-10-13
EP1307225A2 (de) 2003-05-07
US20040076626A1 (en) 2004-04-22
WO2002011767A3 (en) 2002-12-19
US20060280741A1 (en) 2006-12-14
US20020064527A1 (en) 2002-05-30
US20100071079A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
DE60142237D1 (de) Cd30 oder cd30l antagonisten zur behandlung von autoimmun und kronisch entzündlichen zuständen
ATE451930T1 (de) Verwendung von il-18-hemmern zur behandlung oder prävention von sepsis
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE376835T1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
ATE322290T1 (de) Verwendung von cyclooxygenase-2 inhibitor celecoxib und capecitabine zur kombinationsbehandlung von neoplasia
ATE414556T1 (de) Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten
ATE511655T1 (de) Verfahren zur auswertung eines myelounterdrückungszustands
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
NO20056073L (no) Sammensetninger og fremgangsmater til behandling av alvorlig akutt respitatorisk syndrom (SARS)
DE60234873D1 (de) Verwendung von COX-2 Inhibitoren zur Behandlung von affectiven Störungen
ATE345793T1 (de) Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
ATE497809T1 (de) Myricitrin verbindungen zur behandlung von schlafstörungen
ATE395075T1 (de) Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
HRP20050572A2 (en) Pde4 and pde3/4 inhibitors for use in the treatment of cachexia
DE69913548D1 (de) Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
ATE359804T1 (de) Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1- inhibitoren zur behandlung von nierenkrankheiten
ATE371454T1 (de) Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
ATE353667T1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
ATE256461T1 (de) Benutzung von comt-inhibitoren als analgetika
DE602004004883D1 (de) Vegf-antagonisten zur behandlung von diabetes
ATE380558T1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
DE60122898D1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer-kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
ATE486609T1 (de) Furin-hemmer zur behandlung von fibrose und narbenbildung
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
NO20045343L (no) Ny kombinasjon for behandling av luftveisforstyrrelser

Legal Events

Date Code Title Description
8364 No opposition during term of opposition